Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
RheoNet – Registry<br />
Summary<br />
RheoNet-Registry<br />
RheoNet Registry is an integral part of interdisciplinary quality managemen<br />
of <strong>Rheopheresis</strong>.<br />
Based on interdisciplinary cooperation <strong>Rheopheresis</strong> is a safe ambulatory<br />
treatment <strong>for</strong> elderly patients with <strong>AMD</strong>.<br />
RheoNet-Registry will be continuously updated and report on data analysis<br />
<strong>Dry</strong> <strong>AMD</strong> – Indication <strong>for</strong> <strong>Rheopheresis</strong><br />
Results of the controlled randomised MAC-I Trial from Cologne,<br />
+ the controlled Utah-Trial, + MIRA-1 Interimanalysis, + experience of the<br />
Dept. Ophthalmol. at Cologne University with app. 300 Patienten including<br />
long-term treatment, + RheoNet data justify to offer <strong>Rheopheresis</strong> to highrisk<br />
patients with dry <strong>AMD</strong>, who otherwise don‘t have a therapeutic<br />
alternative (in countries with medical device approval, i.e. Europe/Germany<br />
Canada, Japan).
Change language